Literature DB >> 1632938

Left ventricular mass as a measure of preclinical hypertensive disease.

R B Devereux1, M J Koren, G de Simone, M J Roman, J H Laragh.   

Abstract

The ability to identify the hypertensive patient who is destined to suffer a morbid or fatal complication in the long presymptomatic phase of this condition, when its natural history would be most subject to amelioration, is limited by the weak relation between the level of blood pressure and the occurrence of complications. Recent research indicates that the level of left ventricular (LV) mass--most conveniently measured by echocardiography--reflects the combined effects of a variety of factors involved in the pathophysiology of hypertension, including obesity, exaggerated blood pressure responses to everyday activity, high sodium intake and blood viscosity, and genetic factors predisposing to hypertension. Prospective studies indicate that LV mass is a stronger predictor of subsequent morbid events and death than blood pressure or other conventional risk factors except age. Preliminary findings of close relations between LV mass and arterial disease and between the change in LV mass during antihypertensive treatment and subsequent events contribute to explaining the strong predictive value of LV mass. Further research is needed to clarify the biologic basis of these observations and to determine whether stratification of hypertensive patients based on their level of LV mass can improve the treatment of hypertension.

Entities:  

Mesh:

Year:  1992        PMID: 1632938     DOI: 10.1093/ajh/5.6.175s

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

Review 1.  Cardiac manifestations in Fabry disease.

Authors:  A Linhart; J C Lubanda; T Palecek; J Bultas; D Karetová; J Ledvinová; M Elleder; M Aschermann
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

2.  Association of leukocyte telomere length with echocardiographic left ventricular mass: the Framingham heart study.

Authors:  Ramachandran S Vasan; Serkalem Demissie; Masayuki Kimura; L Adrienne Cupples; Charles White; Jeffrey P Gardner; Xiaogian Cao; Daniel Levy; Emelia J Benjamin; Abraham Aviv
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

3.  Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.

Authors:  Ja Hye Kim; Beom Hee Lee; Ja Hyang Cho; Eungu Kang; Jin-Ho Choi; Gu-Hwan Kim; Han-Wook Yoo
Journal:  J Hum Genet       Date:  2016-06-23       Impact factor: 3.172

4.  Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.

Authors:  Saskia M Rombach; Bouwien E Smid; Machtelt G Bouwman; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak
Journal:  Orphanet J Rare Dis       Date:  2013-03-25       Impact factor: 4.123

5.  Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.

Authors:  Christoph Kampmann; Amandine Perrin; Michael Beck
Journal:  Orphanet J Rare Dis       Date:  2015-09-29       Impact factor: 4.123

6.  Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis.

Authors:  Michael Beck; Derralynn Hughes; Christoph Kampmann; Sylvain Larroque; Atul Mehta; Guillem Pintos-Morell; Uma Ramaswami; Michael West; Anna Wijatyk; Roberto Giugliani
Journal:  Mol Genet Metab Rep       Date:  2015-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.